Print this page
-
An Open-label, Expanded Access Protocol for Pediatric Patients with Sickle Cell Disease Who Have No Alternative Treatment Options.
Protocol: 112304Principal Investigator:
- Richard Drachtman M.D. (Rutgers University)
Applicable Disease Sites: Any Site -
A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-Oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma
Protocol: 112305Principal Investigator:
- Richard Drachtman M.D. (Rutgers University)
Applicable Disease Sites: Hodgkin's Lymphoma -
Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT).
Protocol: 112106Principal Investigator:
- Scott Moerdler M.D. (Rutgers University)
Applicable Disease Sites: Kidney -
A Randomized Phase 3 Trial of Vinorelbine, Dactinomycin, and Cyclophosphamide (VINO-AC) Plus Maintenance Chemotherapy with Vinorelbine and Oral Cyclophosphamide (VINO-CPO) vs Vincristine, Dactinomycin and Cyclophosphamide (VAC) plus VINO-CPO Maintenance in Patients with High Risk Rhabdomyosarcoma (HR-RMS) An Intergroup NCTN Phase 3 Study.
Protocol: 112107Principal Investigator:
- Scott Moerdler M.D. (Rutgers University)
Applicable Disease Sites: Any Site -
A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients with Osteosarcoma.
Protocol: 112201Principal Investigator:
- Scott Moerdler M.D. (Rutgers University)
Applicable Disease Sites: Bones and Joints
Lung -
A Phase 2 Study of Bevacizumab, Erlotinib and Atezolizumab in Subjects with Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) Associated or Sporadic Papillary Renal Cell Cancer.
Protocol: 082203Principal Investigator:
- Ryan Stephenson (Rutgers University)
Applicable Disease Sites: Kidney